Patent Oppositions in organic medicines industry

Explore the competitive field of organic medicines where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in organic medicines technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Nov 12, 2026
CompanyTotal Oppositions
NOVARTIS351
BOEHRINGER INGELHEIM169
PFIZER103
NUTRICIA99
CELGENE83
EURO CELTIQUE71
NESTLE71
F HOFFMANN LA ROCHE65
NESTEC63
GILEAD SCIENCES62

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the organic medicines industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the organic medicines industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 12, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Stable Pharmaceutical Composition For Oral AdministrationASTELLAS PHARMANov 12, 2026ALFRED E TIEFENBACHER
Aripiprazole Sustained-Release Microsphere And Preparation Method ThereforLIVZON PHARMACEUTICAL GROUPNov 11, 2026ALKERMES PHARMA IRELAND IE
Combination Formulation Of Two Antiviral CompoundsGILEAD PHARMASSETNov 10, 2026HAMPTON KNOWLES
Crystalline Forms Of N-[4-(Chlorodifluoromethoxy)Phenyl]-6-[(3R)-3-Hydroxypyrrolidin-1-Yl]-5-(1H-Pyrazol-5-Yl)Pyridine-3-CarboxamideNOVARTISNov 5, 2026ELKINGTON AND FIFE
Improved Aquaculture Feed AdditiveHP INGREDIENTSNov 3, 2026MAQUI NEW LIFE
Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanIPSEN BIOPHARMOct 28, 2026LEPTHIEN
Fused Imidazole Derivative, Preparation Method Therefor, And Medical Use ThereofSHANGHAI HENGRUI PHARMACEUTICALOct 28, 2026JAMES POOLE
Infant Or Young Child FormulaNESTLEOct 28, 2026NUTRICIA
Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanIPSEN BIOPHARMOct 27, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD
Composition For Solid Preparation Comprising Hydroxypropyl Methyl Cellulose, Solid Preparation, And Method For Producing The SameSHIN ETSU CHEMICALOct 26, 2026NUTRITION & BIOSCIENCES USA 1

To stay ahead in the competitive organic medicines industry, companies are constantly innovating. Here are the top patents facing oppositions in the organic medicines industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 12, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS24
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA21
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM19
Nov 26, 2025Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIM19
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS19
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS17
Oct 11, 2023New UseNOVARTIS17
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Apr 22, 2015Prevention And Treatment Of Thromboembolic DisordersBAYER HEALTHCARE15